Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 6 , Pages 769-776 , December 2010

Reduced dose-limiting toxicity of intraperitoneal mitoxantrone chemotherapy using cardiolipin-based anionic liposomes

  • Rae Sung Chang, MSc

      Affiliations

    • School of Life Sciences and Biotechnology, Korea University, Seoul, South Korea
    • School of Pharmacy, Seoul National University, Seoul, South Korea
    • These two authors contributed equally to this work.
    • ,
  • Jiyeon Kim, MSc

      Affiliations

    • School of Life Sciences and Biotechnology, Korea University, Seoul, South Korea
    • These two authors contributed equally to this work.
    • ,
  • Han Young Lee, MSc

      Affiliations

    • School of Life Sciences and Biotechnology, Korea University, Seoul, South Korea
    • ,
  • Su-Eun Han, MSc

      Affiliations

    • School of Life Sciences and Biotechnology, Korea University, Seoul, South Korea
    • ,
  • Jinhee Na, MSc

      Affiliations

    • Korea Institute of Science and Technology, Seoul, South Korea
    • ,
  • Kwangmeyung Kim, PhD

      Affiliations

    • Biomedical Research Center, Korea Institute of Science and Technology, Seoul, South Korea
    • ,
  • Ick Chan Kwon, PhD

      Affiliations

    • Biomedical Research Center, Korea Institute of Science and Technology, Seoul, South Korea
    • ,
  • Young Bong Kim, PhD

      Affiliations

    • Department of Animal Biotechnology, Konkuk University, Seoul, South Korea
    • ,
  • Yu-Kyoung Oh, PhD

      Affiliations

    • School of Pharmacy, Seoul National University, Seoul, South Korea
    • Corresponding Author InformationCorresponding author: School of Pharmacy, Seoul National University, Gwanak-gu, Seoul 151-742, South Korea.

Received 18 January 2010 ,Accepted 12 May 2010.

References 

  1. Cotte E, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O. Management of peritoneal carcinomatosis from colorectal cancer: Current state of practice. Cancer J. 2009;15:243–248
  2. Muggia FM. New and emerging intraperitoneal (IP) drugs for ovarian cancer treatment. Semin Oncol. 2006;33:S18–S24
  3. Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy. Cancer J. 2009;15:216–224
  4. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: A systematic review of morbidity and mortality. Ann Surg. 2009;249:900–907
  5. Markman M. Antineoplastic agents in the management of ovarian cancer: Current status and emerging therapeutic strategies. Trends Pharmacol Sci. 2008;29:515–519
  6. Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31:53–58
  7. Lim SJ, Cormier JN, Feig BW, Mansfield PF, Benjamin RS, Griffin JR, et al. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann Surg Oncol. 2007;14:2309–2318
  8. Keese M, Gasimova L, Schwenke K, Yagublu V, Shang E, Faissner R, et al. Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer. Int J Cancer. 2009;124:2701–2708
  9. Lu B, Xiong SB, Yang H, Yin XD, Chao RB. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases. Eur J Pharm Sci. 2006;28:86–95
  10. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: An update review. Curr Drug Deliv. 2007;4:297–305
  11. Madhusudan S, Tamir A, Bates N, Flanagan E, Gore ME, Barton DP, et al. A multicenter Phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res. 2004;10:2986–2996
  12. Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev. 2009;61:850–862
  13. Han SE, Kang H, Shim GY, Suh MS, Kim SJ, Kim JS, et al. Novel cationic cholesterol derivative-based liposomes for serum-enhanced delivery of siRNA. Int J Pharm. 2008;353:260–269
  14. Bertschinger M, Backliwal G, Schertenleib A, Jordan M, Hacker DL, Wurm FM. Disassembly of polyethylenimine-DNA particles in vitro: Implications for polyethylenimine-mediated DNA delivery. J Control Release. 2006;116:96–104
  15. Layman JM, Ramirez SM, Green MD, Long TE. Influence of polycation molecular weight on poly(2-dimethylaminoethyl methacrylate)-mediated DNA delivery in vitro. Biomacromolecules. 2009;10:1244–1252
  16. Srinivasachari S, Liu Y, Prevette LE, Reineke TM. Effects of trehalose click polymer length on pDNA complex stability and delivery efficacy. Biomaterials. 2007;28:2885–2898
  17. Li C, Cui J, Wang C, Li Y, Zhang H, Wang J, et al. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm. 2008;70:657–665
  18. Zucker D, Marcus D, Barenholz Y, Goldblum A. Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. J Control Release. 2009;139:73–80
  19. Cui J, Li C, Wang L, Wang C, Yang H, Li Y, et al. Ni2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation. Int J Pharm. 2009;368:24–30
  20. Mauritz R, Peters GJ, Kathmann I, Teshale H, Noordhuis P, Comijn EM, et al. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo. Cancer Chemother Pharmacol. 2008;62:937–948

 This work has been financially supported by grants from the Ministry of Education, Science and Technology (2009-0081879), 2009 Health & Medical Technology R&D program (Grant No. A090945), and Bio-Green 21 program (Code No. 20100301-061-200-001-03-00), Rural Development Administration, South Korea.

PII: S1549-9634(10)00158-9

doi: 10.1016/j.nano.2010.05.003

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 6 , Pages 769-776 , December 2010

Article Tools

* Image Usage & Resolution